Share on StockTwits

Omnicell (NASDAQ:OMCL) Director Gary S. Petersmeyer unloaded 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 21st. The stock was sold at an average price of $26.51, for a total transaction of $53,020.00. Following the completion of the transaction, the director now directly owns 17,088 shares in the company, valued at approximately $453,003. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Omnicell (NASDAQ:OMCL) traded up 1.26% on Friday, hitting $26.60. 124,869 shares of the company’s stock traded hands. Omnicell has a one year low of $17.83 and a one year high of $30.33. The stock’s 50-day moving average is $26.76 and its 200-day moving average is $26.26. The company has a market cap of $973.7 million and a P/E ratio of 35.60.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, May 1st. The company reported $0.26 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.24 by $0.02. The company had revenue of $101.80 million for the quarter, compared to the consensus estimate of $97.49 million. During the same quarter in the prior year, the company posted $0.21 earnings per share. The company’s quarterly revenue was up 16.9% on a year-over-year basis. On average, analysts predict that Omnicell will post $1.23 earnings per share for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Stephens initiated coverage on shares of Omnicell in a research note on Tuesday. They set an “overweight” rating on the stock. Separately, analysts at Cowen and Company raised their price target on shares of Omnicell from $28.00 to $30.00 in a research note on Friday, May 2nd. Finally, analysts at B. Riley raised their price target on shares of Omnicell to $32.00 in a research note on Friday, May 2nd. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $31.00.

Omnicell, Inc (NASDAQ:OMCL) is a provider of automated solutions for hospital medication and supply management.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.